» Articles » PMID: 15292300

Hyperhomocysteinemia in Patients with Cushing's Syndrome

Overview
Specialty Endocrinology
Date 2004 Aug 5
PMID 15292300
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

We evaluated serum homocysteine concentrations and the C677T polymorphism of the gene encoding for methylene tetrahydrofolate reductase, a key enzyme for homocysteine metabolism, in 57 patients with Cushing's syndrome, 41 with active disease, and 16 in remission after successful surgery and 105 blood donors. The patients with active Cushing's syndrome had significantly higher serum homocysteine levels and lower folate concentrations than either the patients in remission or controls. The presence of a statistically significant difference in homocysteine concentrations among the three groups was confirmed after adjustment for confounding variables. In a multiple regression model, homocysteine levels were significantly associated with midnight serum cortisol levels (beta = 0.33, P = 0.01), which is the most sensitive marker of endogenous hypercortisolism, and serum folate levels (beta = -0.32, P = 0.02). The distribution of methylene tetrahydrofolate reductase genotypes was not different between patients and controls. In conclusion, active hypercortisolism is associated with hyperhomocysteinemia and reduced serum folate concentrations, whereas the patients in remission have homocysteine concentrations comparable with healthy subjects. Low serum folate concentrations do not fully account for the increase in homocysteine levels that are positively correlated with cortisol levels. Hyperhomocysteinemia may be key to the prothrombotic state and increased cardiovascular risk of Cushing's syndrome.

Citing Articles

Association between Neutrophilic Granulocyte Percentage and Diabetes Mellitus in Cushing's Syndrome Patients: A Cross-Sectional Study.

Wang B, Yang Y, Yuan H, Li X Int J Endocrinol. 2021; 2021:9536730.

PMID: 34880914 PMC: 8648481. DOI: 10.1155/2021/9536730.


Acute severe Cushing's disease presenting as a hypercoagulable state.

Fariduddin M, Syed W, Divan V, Nadkarni P, Dhaliwal R Proc (Bayl Univ Med Cent). 2021; 34(6):715-717.

PMID: 34732999 PMC: 8545141. DOI: 10.1080/08998280.2021.1953950.


Evaluation of procoagulant imbalance in Cushing's syndrome after short- and long-term remission of disease.

Ferrante E, Serban A, Clerici M, Indirli R, Scalambrino E, Carosi G J Endocrinol Invest. 2021; 45(1):9-16.

PMID: 34115342 PMC: 8741706. DOI: 10.1007/s40618-021-01605-5.


Hypercoagulability and Risk of Venous Thromboembolic Events in Endogenous Cushing's Syndrome: A Systematic Meta-Analysis.

Wagner J, Langlois F, Lim D, McCartney S, Fleseriu M Front Endocrinol (Lausanne). 2019; 9:805.

PMID: 30745894 PMC: 6360168. DOI: 10.3389/fendo.2018.00805.


Impairment of Arterial Compliance in Cushing's Syndrome.

Bassareo P, Maria Zedda A, Mercuro G Eur Endocrinol. 2018; 10(2):161-164.

PMID: 29872483 PMC: 5983088. DOI: 10.17925/EE.2014.10.02.161.